Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
American Oncology Network, Inc. incurred loan of $50,000 with Digital Transformation Sponsor LLC at non-interest bearing maturing upon the earlier of (i) the date of the consummation of the Company’s initial business combination and (ii) the date of the liquidation of the Company.
- Instrument
- loan
- Principal
- $50,000
- Counterparty
- Digital Transformation Sponsor LLC
- Rate
- non-interest bearing
- Maturity
- upon the earlier of (i) the date of the consummation of the Company’s initial business combination and (ii) the date of the liquidation of the Company
- Event
- incurrence
Exact text from the filing
the Company is required to complete its initial business combination from August 31, 2023 to September 30, 2023. In accordance with the Company’s charter, the Sponsor deposited $50,000 into the trust account established for the benefit of the Company’s public stockholders, which was evidenced by a non-interest bearing, unsecured promissory note issued in favor
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
American Oncology Network, Inc. entered into Extension Note with Digital Transformation Sponsor LLC valued at $50,000 (effective 2023-08-21).
- Action
- entry
- Counterparty
- Digital Transformation Sponsor LLC
- Value
- $50,000
- Effective
- 2023-08-21
Exact text from the filing
On August 21, 2023, Digital Transformation Sponsor LLC (the “Sponsor”) delivered written notice to Digital Transformation Opportunities Corp. (the “Company”), regarding its exercise of the option to extend the date by which the Company is required to complete its initial business combination from August 31, 2023 to September 30, 2023. In accordance with the Company’s charter, the Sponsor deposited $50,000 into the trust account established for the benefit of the Company’s public stockholders, which was evidenced by a non-interest bearing, unsecured promissory note issued in favor of the Sponsor (the “Extension Note”).
View on SEC.gov